

## Amondys-45™ (casimersen) (Intravenous)

Effective Date: 05/01/2021

Review Date: 4/22/2021, 02/24/2022

Revision date: 4/22/2021

Scope: Medicaid, Commercial, Medicare-Medicaid Plan (MMP)

### I. Length of Authorization

Authorization is valid for 6 months and may be renewed.

### II. Dosing Limits

#### A. Quantity Limit (max daily dose) [NDC unit]:

- Amondys-45 100 mg vial: 35 vials per 7 days

#### B. Max Units (per dose and over time) [HCPCS Unit]:

- 350 billable units every 7 days

### III. Initial Approval Criteria <sup>1-5</sup>

Coverage is provided in the following conditions:

MMP members who have previously received this medication within the past 365 days are not subject to Step Therapy Requirements.

#### Universal Criteria

- Patient is not on concomitant therapy with other DMD-directed antisense oligonucleotides (e.g., eteplirsen, golodirsen, viltolarsen, etc.); **AND**
- Patient serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio (UPCR) are measured prior to starting therapy and periodically during treatment; **AND**

#### Duchenne muscular dystrophy (DMD) † Φ

- Patient must have a confirmed mutation of the *DMD* gene that is amenable to exon 45 skipping; **AND**
- Patient has been on a stable dose of corticosteroids, unless contraindicated or intolerance, for at least 3 months; **AND**

- Patient retains meaningful voluntary motor function (e.g., patient is able to speak, manipulate objects using upper extremities, ambulate, etc.); **AND**
- Patient should be receiving physical and/or occupational therapy; **AND**
- Baseline documentation of one or more of the following:
  - Dystrophin level
  - 6-minute walk test (6MWT) or other timed function tests
  - Upper limb function (ULM) test
  - North Star Ambulatory Assessment (NSAA)
  - Forced Vital Capacity (FVC) percent predicted

† FDA-labeled indication(s), ‡ Compendia recommended indication(s); ◻ Orphan Drug

#### IV. Renewal Criteria <sup>1</sup>

- Patient continues to meet universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in section III; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include the following: severe hypersensitivity reactions, renal toxicity/proteinuria, etc.; **AND**
- Patient has responded to therapy compared to pretreatment baseline in one or more of the following (not all-inclusive):
  - Increase in dystrophin level
  - Stability, improvement, or slowed rate of decline in 6MWT or other timed function tests
  - Stability, improvement, or slowed rate of decline in ULM test
  - Stability, improvement, or slowed rate of decline in NSAA
  - Stability, improvement, or slowed rate of decline in FVC% predicted
  - Improvement in quality of life

#### V. Dosage/Administration

| Indication                  | Dose  |
|-----------------------------|---|
| Duchenne muscular dystrophy | Administer 30 mg/kg via intravenous infusion once weekly. |

|  |  |
|--|--|
|  | – Serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio (UPCR) should be measured before starting therapy. Consider measurement of glomerular filtration rate prior to initiation of Amondys 45. |
|--|--|

Store refrigerated at 2°C to 8°C. Do not freeze. Protect from light.

## VI. Billing Code/Availability Information

HCPCS Code:

- J1426 – injection, casimersen, 10mg

NDC:

- Amondys-45 100 mg/2 mL single-dose vial: 60923-0227-xx

## VII. References

1. Amondys 45 [package insert]. Cambridge, MA; Sarepta Therapeutics, Inc.; January 2022. Accessed February 2022.
2. Topaloglu H, Gloss D, Moxley RT 3<sup>rd</sup>, et al. Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology*. 2016 Jul 12;87(2):238.
3. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. *Lancet Neurol*; 2010 Jan; 9(1):77-93.
4. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. *Lancet Neurol*; 2010 Jan; 9(2):177-189.
5. Sarepta Therapeutics. A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy. Available from: <https://clinicaltrials.gov/ct2/show/NCT02500381?term=NCT02500381&draw=2&rank=1>. NLM identifier: NCT02500381. Accessed March 3, 2021.
6. Darras BT, Urion DK, Ghosh PS. Dystrophinopathies. *GeneReviews*. [www.ncbi.nlm.nih.gov/books/NBK1119/](http://www.ncbi.nlm.nih.gov/books/NBK1119/) (Accessed on March 19, 2021)

## Appendix 1 – Covered Diagnosis Codes

| ICD-10 | ICD-10 Description                    |
|--------|---------------------------------------|
| G71.01 | Duchenne or Becker muscular dystrophy |

## Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Articles (LCAs) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: <http://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx>. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCA/LCD): N/A

| Medicare Part B Administrative Contractor (MAC) Jurisdictions |   |   |
|---|---|---|
| Jurisdiction  | Applicable State/US Territory   | Contractor  |
| E (1)   | CA, HI, NV, AS, GU, CNMI  | Noridian Healthcare Solutions, LLC                |
| F (2 & 3)   | AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ  | Noridian Healthcare Solutions, LLC                |
| 5   | KS, NE, IA, MO  | Wisconsin Physicians Service Insurance Corp (WPS) |
| 6   | MN, WI, IL  | National Government Services, Inc. (NGS)          |
| H (4 & 7)   | LA, AR, MS, TX, OK, CO, NM  | Novitas Solutions, Inc.                           |
| 8   | MI, IN  | Wisconsin Physicians Service Insurance Corp (WPS) |
| N (9)   | FL, PR, VI  | First Coast Service Options, Inc.                 |
| J (10)  | TN, GA, AL  | Palmetto GBA, LLC                                 |
| M (11)  | NC, SC, WV, VA (excluding below)  | Palmetto GBA, LLC                                 |
| L (12)  | DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA) | Novitas Solutions, Inc.                           |
| K (13 & 14)   | NY, CT, MA, RI, VT, ME, NH  | National Government Services, Inc. (NGS)          |
| 15  | KY, OH  | CGS Administrators, LLC                           |